The Board has considered and took on record the Un-audited financial results of the company for the quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.0 pts less than Nifty Microcap 250 and 10.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Samrat Pharmachem's Board approved unaudited results for the quarter ended December 31, 2025. Revenue from operations for Q3 FY26 was ₹6,342.61 lakhs, down about 20% from ₹7,887.03 lakhs in the previous quarter (Q2 FY26), and roughly flat compared to ₹6,366.12 lakhs in Q3 FY25. For the nine months ended December 31, 2025, revenue grew modestly to ₹21,794.80 lakhs from ₹21,465.74 lakhs a year earlier. The company slipped into a loss, posting a Q3 loss after tax of ₹45.95 lakhs against a profit of ₹278.48 lakhs in Q3 FY25, and a nine-month loss of ₹127.57 lakhs versus a profit of ₹751.14 lakhs in the same period last year. Total expenses exceeded total income, with cost of materials rising and finance costs nearly doubling year-on-year. The statutory auditor issued an unqualified limited review report.
The swing from profit to loss, combined with a sharp quarter-on-quarter revenue drop and rising finance costs, signals near-term stress for shareholders and is likely to weigh negatively on the stock price. Investors should watch for management commentary on demand recovery and margin restoration in Q4.